Neuroprotective effect of silymarin against 3-Nitropropionic acid-induced neurotoxicity in rats

Priyanka Chandoliaa, Vikrant Rahia, Puneet Kumarb,*

a Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, India
b Department of Pharmacology, Central University of Punjab, Ghudda, Bathinda, India

ARTICLE INFO

Keywords:
Oxidative stress markers
3-NPA- 3-Nitropropionic acid
Mitochondrial dysfunction
Silymarin
Glutamate
HD- Huntington’s disease

ABSTRACT

(HD) Huntington's disease is a severe hereditary catastrophic neurological disease with an autosomal dominant heritable changes manifested by cognitive, behavioural, and motor progression deficits, resulting in death. Several mechanisms are involved in the pathogenesis of this complex and rare disease, including excitotoxicity, mitochondrial dysfunction, neurotransmitters imbalance, and oxidative stress. Silymarin was selected as an investigational drug, due to its numerous activities in current research, it possesses substantial antioxidant and neuroprotective functionalities. The present research attempts, i.p. injections of 3-NPA (10 mg/kg) were given for 21 days to trigger Huntington-like symptoms in rats. The percentage fluctuations in body weight, the footfall counts, and the time required to transverse the beam and motor functions were analyzed at multiple time points. Oxidative stress markers like MDA/LPO, GSH, protein, nitrite, catalase, and superoxide dismutase levels were examined in the striatum region. The current study results conclusively demonstrate that chronic 3-NPA administration significantly decreased the body weight and showed marked abnormalities in motor coordination, locomotion, and increased striatal generation of free radicals. Furthermore, treatment with silymarin (100 & 200 mg/kg/p.o.), mitigated 3-NPA triggered behavioural and biochemical alterations. Our study results could conclude that Silymarin may be advantageous and might develop an adjuvant treatment for the management of Huntington's disease.

1. Introduction

(HD) Huntington disease is a severe hereditary catastrophic neurological disease with an autosomal dominant heritable changes manifest as abnormal body movements, i.e. chorea, psychiatric disorders, and cognitive impairment in the brain region, including the basal ganglia, cerebral cortex, and hippocampus (Jamwal and Kumar, 2018), (Kumar et al., 2010). Alteration of neurotransmitters level in cortex and neostriatum (caudate and putamen) leads to neurological symptoms due to neuronal and axonal loss (Wang et al., 2017), (Suganya and Sumathi, 2016). Although the exact mechanisms underlying the neuropathology of HD-induced striatal neurotoxicity are still not fully comprehended, various conceptions and assumptions have been presented as a means of explaining the mechanism and pathways of HD progression, including the interaction of expanded polyglutamine repeat protein with other proteins in the brain (CNS) (Xiang et al., 2018), apoptosis (Wang et al., 2015a), excitotoxicity (Domise and Vingtdeux, 2016), oxidative stress (Kim et al., 2015), neuroinflammation (Fisher and Hayden, 2014), (Evans et al., 2013), abnormal mitochondrial bioenergetics and impairment of axonal trafficking (Jimenez-Sanchez et al., 2017). However, the precise processes underlying HD neuropathology is not thoroughly comprehended.

The mitochondrial toxin 3-NPA (mycotoxin) permanently inhibits (SDH) succinate dehydrogenase enzymes (mitochondrial complex II) with massive deterioration of medium spiny neurons with GABAergic input (MSNs) (Huang et al., 2006), (Kumar et al., 2012a). Chronic usage of 3-NPA causes mitochondrial dysfunction and reactive oxygen species formation, and changes in various intercellular processes (Garcia et al., 2002). Cell death event results from the 3-NPA induced deregulations of multiple downstream processes that mimic the HD brain's pathophysiology (Gonchar et al., 2021). Therefore, due to the resemblance of 3-NPA in the pathophysiological processes of HD, this model is enlisted as the most reliable animal model to study HD.

A limited number of approaches are available to treat such disorders. Therefore, quality of life is improved by delaying the beginning or retarding the development of neurodegenerative diseases (Durães et al., 2022).
Neurodegenerative disorders are usually managed using various therapeutic strategies. Recent evidence suggests that antioxidants and anti-inflammatory agents of natural origin can prevent/delay damage and cell death when used concomitantly with several neurotoxins. Silymarin, a flavonolignan originating from the milk thorn plant seeds (Valkov et al., 2020), Apart from ability to cross the blood brain barrier (BBB), silymarin have proven antioxidant, anti-apoptotic, anti-inflammatory and enzyme inhibitory activities and represent its potential by providing protection of neurons against oxidative insults in the brain under distress. Its mechanism of action makes this molecule different form other neuronal moieties. Its diverse mechanism of action includes general antioxidant nature to specific anti-amyloidogenic, pro-estrogenic, anti-inflammatory properties (Borah et al., 2013). Previous data represents good neuroprotective features and has a broad spectrum of pharmacological actions, including upregulating glutamate transporter (GLUT-transporter), antioxidant activity, anti-inflammatory, and proven to exhibit neuroprotective properties around the series of estrogenic, anti-inflammatory nature to specific anti-amyloidogenic, pro-estrogenic, anti-inflammatory properties (Borah et al., 2013). Recent evidence suggests that antioxidants and anti-inflammatory agents of natural origin can prevent/delay damage and cell death when used concomitantly with several neurotoxins. Silymarin, a flavonolignan originating from the milk thorn plant seeds (Valkov et al., 2020), Apart from ability to cross the blood brain barrier (BBB), silymarin have proven antioxidant, anti-apoptotic, anti-inflammatory and enzyme inhibitory activities and represent its potential by providing protection of neurons against oxidative insults in the brain under distress. Its mechanism of action makes this molecule different form other neuronal moieties. Its diverse mechanism of action includes general antioxidant nature to specific anti-amyloidogenic, pro-estrogenic, anti-inflammatory properties (Borah et al., 2013). Previous data represents good neuroprotective features and has a broad spectrum of pharmacological actions, including upregulating glutamate transporter (GLUT-transporter), antioxidant activity, anti-inflammatory, and proven to exhibit neuroprotective properties around the series of estrogenic, anti-inflammatory nature to specific anti-amyloidogenic, pro-estrogenic, anti-inflammatory properties (Borah et al., 2013). The empirical study investigate the impacts of Silymarin against 3-NPA induced Huntington disease in experimental wistar rats (Chandolia, 2021).

2. Methods and materials

2.1. Experimental rodents

The empirical research attempts, wistar rodents (either sex) weighed 200–250g, aged-matched (to avoid variability) was acquired from the MRSPTU, major animal house in Punjab (Bathinda) India. These rodents were housed in polycrylic containers and were subjected to regular laboratory procedures, including 12 h light/dark cycle, 22-degree Celsius room temperature as well as humidity levels maintained up to 55 to 60 percent. RO filtered water and food stuffs were available at all times. All behaviour examinations occurred between 9:15 a.m. to 6:00 p.m. The research was authorised under two separate protocols with unique reference no.MRSPTU/IAEC/2019/05. The protocol was performed in accordance with the criteria of CPCSEA and approved by the IAEC.

2.2. Groups of experimentalist

36 animals were assigned, and six animals were randomly entrusted to each different treatment group. The experimental groups (Table 1).

2.3. Drugs and chemicals

Sigma Aldrich Chemicals Pvt. Ltd, Bangalore (India) supplied the Silymarin and 3-NPA. Biochemicals and other chemicals and employed in this investigation had higher analytical scores.

2.4. Treatment schedule

To induce HD-like symptoms, 3-NPA was disseminated in buffered saline at an appropriate 7.4 pH level (given once a day by i.p. route during 21 days at a dosage of 10 mg/kg). Silymarin (50, 100, and 200 mg/kg) was diluted in saline and given orally half an hour before treatment with 3-NPA. Bodyweight and behavioural parameters like rotarod, locomotor activity, open field activity, and narrow beam walk were assessed weekly for 21 days. Terminally on the 22nd day, to estimate biochemical parameters, the striatum was isolated after the animals were sacrificed, and biochemical parameters such as catalase, peroxidation of lipids, nitrite, glutathione reduction, estimation of proteins, and superoxide dismutase were estimated.

2.5. Determination of rat’s body weight

Body weight of wistar rats was determined before and after 3-NPA administration on day 1st and then on day 22nd of the current study. The % weight change was computed by utilizing the given formula below (Kumar et al., 2012b), (Kumar et al., 2011).

Body weight change = Body wght. (1st day-21st day) / 1st day body wght. × 100

2.6. Evaluation of behavioural action

2.6.1. Rotarod workout

At weekly intervals, motor coordination, grip strength, and integrity of animals were evaluated (IMCORP, Ambala, India) with the help of rotarod as described in the literature (Khan et al., 2015), (Kumar et al., 2012c). The rotarod apparatus consists of a non-slippery rod divided into four equal sections. A prior training session was used to acclimatise the rat to the equipment. In both studies, the rats were placed on a 7-cm-diameter spinning rod (speed 25 rotation per minute). Time limit was set at 180 s to measured fall-off latency (Bishnoi et al., 2008), (Datta et al., 2016).

2.6.2. Open field test

VJ instrument was used to record the behaviour of all animals at the end of the investigation framed above the open field square. To monitor locomotor activity, all rats were quietly put on a black wooden apparatus (OFT) comprising 36 squares. The experimentation area was entirely dark, with only an artificial illumination to assist the video monitoring system. Before behavioral evaluations, animals were given 5 min to acclimatise and investigate the surroundings. A video monitoring system monitored the open field investigations, including the amount of squares walked traversed distance (with all paws), traveled, time allocated with movement (active time), time spent not moving (passive time), and average speed through (VJ instruments, India) (Aswar et al., 2017). The final value was calculated by averaging the 3 times monitored activity throughout the experiment, with a cutoff duration of 10 min. After exposure to the For 10 min, rats were distress in places (a rectangular shaped wooden enclosure) had been sanitized by using ethanol at a previous rate of 70% conducting this event.

2.6.3. Narrow beam walking test

A narrow beam (8 cm in diameter) was employed in this work, which was connected by a cylindrical steel rod (thickness of 0.5 mm, width of 2.0 cm, with a 120 cm length). The beam was raised 1 m above floor level. To cushion the rat's landing, under the beam sawdust-filled box was levelled. Before training, the rats were given 5 min to adjust to the new environment. In each trial, the count of slips and how long it would take a rat to traversed beam from one end to the other were recorded. The final value was calculated by averaging the three recorded transfer latencies, and the inter-trial period was conducted for 2 min (Khan et al., 2015), (Kumar et al., 2012c).

2.6.4. Striatal tissue homogenate preparation

On day 22nd, rats were euthanized, and their brains were taken and preserved in a refrigerator at –20 °C until they could be analyzed. Deeply

Table 1

| Sr. No. | Groups                                                                 |
|--------|-----------------------------------------------------------------------|
| 1.     | Vehicle control                                                       |
| 2.     | 3-NPA treated groups (10 mg/kg/i.p./day) for 21 days                  |
| 3.     | Silymarin (50mg/kg/p.o./day) + 3-NPA (10mg/kg/i.p./day) for 21 days    |
| 4.     | Silymarin (100mg/kg/p.o./day) + 3-NPA (10mg/kg/i.p./day) for 21 days   |
| 5.     | Silymarin (200mg/kg/p.o./day) + 3-NPA (10mg/kg/i.p./day) for 21 days   |
| 6.     | Silymarin/Place (200mg/kg/p.o./day) for 21 days                       |

2018). Neurodegenerative disorders are usually managed using various therapeutic strategies. Recent evidence suggests that antioxidants and anti-inflammatory agents of natural origin can prevent/delay damage and cell death when used concomitantly with several neurotoxins. Silymarin, a flavonolignan originating from the milk thorn plant seeds (Valkov et al., 2020), Apart from ability to cross the blood brain barrier (BBB), silymarin have proven antioxidant, anti-apoptotic, anti-inflammatory and enzyme inhibitory activities and represent its potential by providing protection of neurons against oxidative insults in the brain under distress. Its mechanism of action makes this molecule different form other neuronal moieties. Its diverse mechanism of action includes general antioxidant nature to specific anti-amyloidogenic, pro-estrogenic, anti-inflammatory properties (Borah et al., 2013). Previous data represents good neuroprotective features and has a broad spectrum of pharmacological actions, including upregulating glutamate transporter (GLUT-transporter), antioxidant activity, anti-inflammatory, and proven to exhibit neuroprotective properties around the series of estrogenic, anti-inflammatory nature to specific anti-amyloidogenic, pro-estrogenic, anti-inflammatory properties (Borah et al., 2013).
frozened brains were evacuated on the day of the experiment, in addition, the striatum was separated by positioning them on ice bags, weighing them, and homogenising them with phosphate buffer (0.1 Molar) with the pH 7.4. After centrifuging homogenization was done for 15 min at 10,000 g, all aliquots of the supernatant were separated and used for biochemical examination.

2.7. Oxidative stress parameters prediction

2.7.1. Calibration of malon-di-aldehyde
To quantify the MDA-end product, a quantitative assessment of LPO levels in the striatum of the brain, and cortical regions was performed applying (Wills methodology), which was introduced in 1966 (Wills, 1966). By accessing a Shimadzu spectrophotometer at 532 nm, optical density was measured.

2.7.2. Quantification of nitrite
The Griess reagent (0.1 percent N-(1-naphthyl) ethylenediamine dihydrochloride, 2.5 percent phosphoric acid, and 1 percent sulfanilamide was used to estimate nitrite deposition in the striatum supernatant homogenate (Green et al., 1982). A UV spectrophotometer at 540 nm, was utilized to identify absorbance.

2.7.3. Quantification of the depletion of glutathione levels
Ellman’s method was used to estimate the depletion of glutathione (GSH) in the brain’s striatum and cortical areas (Ellman, 1959).

2.7.4. Protein quantification
The Lowry procedure, which uses Folin phenol as a reagent, was used to test protein levels in the brain’s striatum and cortical areas (Gornall et al., 1949).

2.7.5. Measurement of catalase
Activity of catalase was determined with techniques outlined by Luck et al., where the distension of H₂O₂ was measured at 230 nm (Luck, 1963) only for 2 min intervals by using a Shimadzu UV/visible spectrophotometer.

2.7.6. Assessment of super-oxide dismutase content
Super-oxide dismutase content was examined by using approach given by Kono et al., (1978) (Kono, 1978).

2.8. Statistic validation
The assembled data is represented as Standard Mean Deviation. Two-way (ANOVA) had been used to investigate the behavioral data, proceeded by Bonferroni’s post hoc analysis for a couple of correlations. A one-way ANOVA is used to make the correlations of biochemical parameters, proceeded by Tukey’s post hoc analysis.

3. Results

3.1. SILY’s effect on body weight in rats injected 3-NPA
The first and last body weights of the controlled animals did not differ significantly. 3-NPA treatment via intraperitoneal route with dose (10 mg/killogram/day) results (P < 0.001) steady weight decrease in correlation to control. Pretreatment with silymarin via orally route at various two dosage (100 & 200 mg/killogram) substantially (p < 0.001) greatly lowered the decline in body weight in comparison to 3-NPA treated group whereas low dose of silymarin via orally route with dose (50 mg/kg) and higher dose (200 mg/kg) perse demonstrated no substantial difference between the 3-NP and control-treated groups, respectively (Fig. 1).

3.2. SILY’s effect on the time to cross and the number of foot slips on a narrow beam walking device in 3-NPA treated rats
The first and last body weights of the controlled animals did not differ significantly. 3-NPA treatment via intraperitoneal route with dose (10 mg/killogram/day) results (P < 0.001) steady weight decrease in correlation to control. Pretreatment with silymarin via orally route at various two dosage (100 & 200 mg/killogram) substantially (P < 0.05) reduces the counts of footfalls and time it takes to transverse the beam as compared to the 3-NP group. Whereas smaller doses of silymarin via orally routes with dose (50 mg/killogram) and higher dose (200 mg/killogram) perse showed no substantial effect as correlation to 3-NPA and
control-treated groups, respectively (Fig 2A; 2B).

3.3. SILY’s effect on 3-NPA-triggered modifications in rotarod activity

3-NPA via intraperitoneal route at a dose (10 mg/kilogram) produced a substantial ($p < 0.01$) lower rotarod activity on the 14th and 21st day as correlated with control group (Fig. 3). Silymarin as a pre-treatment via orally route at various two dosage (100 & 200 mg/kg) substantially ($p < 0.05$) averted rotarod activity deficit in correlation to 3-NPA treated rats. A smaller dose of silymarin via orally route (50 mg/kg) and a higher dose (200 mg/kg) perse had no substantial effect on rotarod activity comparison compared with 3-NPA and control-treated groups, respectively.

3.4. SILY’s effect on open field test (OFT) for motor coordination in 3-NPA-treated rats

The (Maze Master 3.0) video monitoring software system monitored
the action of 3-NPA animals were treated that show a remarkable reduction in crossings, total distance, average speed, active time and increased passive time on the seventh, fourteenth, and twenty-first days in comparison to control group. In contrast, pre-treatment with silymarin via orally route (100 & 200 mg/kg) substantially (p < 0.05) reversed the 3-NPA induced behavioural alteration. (Fig 4 A, B, C, & D).

3.5. SILY’s effect on nitrite levels in rats exposed 3-NP-induced neurotoxicity

The nitrite level in the striatum of the 3-NPA, when correlated to the controlled group, the treated group grew considerably (p < 0.001). Silymarin as a pre-treatment via orally route at other two doses (100 & 200 mg/kg) decreased the nitrite level correlated to the 3-NPA group (Table 2) & (Fig. 5).

3.6. SILY’s effect on MDA levels in rats exposed to 3-NP-induced neurotoxicity

MDA levels inside the striatum, 3-NPA treated group increased significantly (P < 0.001), indicating a significant increase in lipid per-oxidation. Repeated administration of silymarin via orally with dose of (100 & 200 mg/kg) significantly (P < 0.001) prevents the elevation in the MDA levels compared to the 3-NP group and vehicle treatment. A low
dose of Silymarin via orally route with dose of (50 mg/kg) did not significantly affect brain MDA levels (Table 2) & (Fig. 6).

3.7. Silymarin’s effect on glutathione levels in rats exposed to 3-NPA-induced neurotoxicity

The GSH level inside the striatum, 3-NPA treated group was considerably lower (P < 0.001) than the controlled group on the 21st day. Silymarin as a pre-treatment via orally route at dosage of (100 & 200 mg/kg) increases the GSH level in comparison to the 3-NPA group and vehicle treatment. However, silymarin (50 mg/kg) demonstrated no statistically significant influence (Table 2) & (Fig. 7).

Fig. 4B. Effect of silymarin on average speed in open field apparatus in 3-NP treated rats (n = 6). Data analyzed by two-way repeated-measures ANOVA followed by Bonferroni’s multiple comparison. *p<0.001 versus control, ^p < 0.05 versus 3-NP.

3-NP = 3-Nitropropionic acid, SILY= Silymarin.

Fig. 4C. Effect of silymarin on total distance traveled in open field apparatus in 3-NP treated rats (n = 6). Data analyzed by two-way repeated-measures ANOVA followed by Bonferroni’s multiple comparison. *p<0.001 versus control, ^p < 0.05 versus 3-NP.

3-NP = 3-Nitropropionic acid, SILY= Silymarin.

dose of Silymarin via orally route with dose of (50 mg/kg) did not significantly affect brain MDA levels (Table 2) & (Fig. 6).

3.7. Silymarin’s effect on glutathione levels in rats exposed to 3-NPA-induced neurotoxicity

The GSH level inside the striatum, 3-NPA treated group was considerably lower (P < 0.001) than the controlled group on the 21st day. Silymarin as a pre-treatment via orally route at dosage of (100 & 200 mg/kg) increases the GSH level in comparison to the 3-NPA group and vehicle treatment. However, silymarin (50 mg/kg) demonstrated no statistically significant influence (Table 2) & (Fig. 7).
3.8. SILY’s effect on catalase levels in rats exposed to 3-NPA-induced neurotoxicity

3-NPA given at a systemic dose significantly (P < 0.001) inhibited the catalase intensity as compared with the control in the striatum on the 21st day. Silymarin as a pre-treatment via orally route at two respective doses (100 & 200 mg/kg) increases the catalase intensity compared with 3-NPA group and vehicle treatment. Moreover, silymarin via orally route (50 mg/kg) demonstrated no statistically significant influence (Table 2) & (Fig. 8).

3.9. SILY’s effect on SOD levels in rats exposed to 3-NPA-induced neurotoxicity

3-NPA given at a systemic dose substantially (P < 0.001) reduced the SOD intensity as correlated with the controlled in the striatum on the 21st day. Silymarin as a pre-treatment via orally route at two respective doses (100 & 200 mg/kg) increased the SOD and control group. Moreover, silymarin via orally route (50 mg/kg) demonstrated no statistically significant influence (Table 2) & (Fig. 9).

4. Discussion

The current study’s findings indicates the neuroprotective potential of silymarin’s against 3-NPA triggered neurotoxicity in rats. In this studies, rats were given i.p. injections of 3-NPA (10 mg/kg) for 21 days that showed behavioral alterations and produced chronic motor deficiency, increase in the count of footfalls as well as time took to cross the beam on narrow beam walk performance indicating stable motor impairment and striatal dysfunctioning. It was markedly overturned by the administering of silymarin in a dose-dependent manner. In comparison to the vehicle-treated group, the 3-NPA-treated group lost weight substantially. Furthermore, biochemical analysis revealed that silymarin (100 & 200 mg/kg) p.o.administration considerably lowered 3-NPA induced oxidative (elevation in lipid peroxidation) and nitrosative (elevated nitrite) stress in the striatum region of rats brain. Furthermore, chronic administration of 3-NPA lowered superoxide dismutase (SOD), glutathione (GSH) and catalase amounts which were significantly increased by silymarin in a dose-dependent manner.

However, the precise pathways producing neuropathology in movement disorders are uncertain, many pathways relating to...
neurotransmitter changes such as excitotoxic neuronal death, oxidative stress, mitochondrial malfunction, and neuroinflammation have been proposed in the literature (Singh et al., 2015), (Kumar and Kumar, 2009a) responsible for alteration in neuropathology. 3-NPA irreversibly blocks the enzyme SDH, which results in decreased levels of ATP, and neuronal cell death may be observed (Kumar and Kumar, 2009b), (Túnez et al., 2011). However, the specific pathophysiology of SDH silencing is yet unknown. Studies suggested that the dianion form of the toxin's carbanion more likely binds to the site of substrate to be oxidised into 3-nitroacrylic acid, that can reacted with the substrate site's thiol group to form a covalent adduct (Coles et al., 1979). It was recently discovered that 3-NPA produces a covalent adduct with the catalytic base arginine complex II after oxidation. The 3-NPA rapidly penetrates the blood-brain barrier, inactivating SDH activity within 2 h of intraperitoneal injection, and can be given systemically to rats, mice, and non-human primates. Depending on the time course of treatment, the 3-NPA model can emulate both hyperkinetic and hypokinetic HD symptoms (Wiprich et al., 2020). Thus 3-NPA toxicity results in ATP and energy levels reduction, calcium homeostasis disruption, excitotoxicity events, and neuronal death (Kumar and Kumar, 2009a). The death of excitotoxic cells has formation of oxidative stress and reactive oxygen species (ROS) has been related. Extracellular glutamate accumulation result in defected glutamate transmission and has been identified as a target for treatment in HD (Kraskovskaya and Bezprozvanny, 2021). Glutamate is the most widely known as neurotransmitter (EAA) excitatory amino acid in mammals, and open ligand-gated ion channels such NMDA, G-protein-coupled metabotropic, kainite and AMPA receptors. Due to accumulation and over-activation of EAA receptors, cell death of neurons can be found within acute and chronic neurodegenerative conditions, including ALS, HD, AD, and behavioural disorders like depression (Gegelashvili et al.,

**Fig. 5.** Effect of silymarin on nitrite level in 3-NP treated rats. Values are expressed as mean ± S.D. *p < 0.001 as compared to control, †p < 0.001 as compared to 3-NP.

3-NP = 3-Nitropropinic acid, SILY = Silymarin.

**Fig. 6.** Effect of silymarin on Lipid peroxidation level (LPO) in 3-NP treated rats. Values are expressed as mean ± S.D. *p < 0.001 as compared to control, †p < 0.001 as compared to 3-NP.

3-NP = 3-Nitropropinic acid, SILY = Silymarin.
Hence, the gait abnormalities observed in the present study are in accordance with previous researches following 3-NP administration (Rodríguez-Campuzano and Ortega, 2021).

On the other hand, Silymarin is the polyphenolic flavonoid derived from Silybum marianum dried fruit, which has been used very frequently since ancient times for hepatoprotective activities (Wang et al., 2015b), (AbouZid et al., 2016). Because of its comprehensive medicinal properties, it is one of the most commonly used flavonoids among phytochemicals (Mady et al., 2016; Pogačnik et al., 2020; Singhal et al., 2011; Baluchnejadmojarad et al., 2010). Silymarin has been reported to be safe in various pathological conditions such as kidney, liver, CNS, pancreas, and skin (Pogačnik et al., 2020). Silymarin is known to have antioxidant and anti-apoptotic properties (Singhal et al., 2011). Its antioxidant action has been demonstrated to be beneficial in animal models of PD and AD (Baluchnejadmojarad et al., 2010).

In the current research, Silymarin significantly attenuates the behavioral and biochemical alterations induced by 3-NPA. It is found that Silymarin possesses significant neuroprotective effects against 3-NPA induced biochemical and behavioral alterations. Silymarin therapy at doses of (100 & 200 mg/kg/oral) dramatically minimize lipid peroxidation and concentrated nitrite extent in striatum of the brain, while also preserving antioxidant enzyme levels indicating putative antioxidant activity. All these results are in good agreement with previous studies (Kumar and Kumar, 2009b). Furthermore, apart from antioxidant activity in association with scavenging of free radicals, its mechanism include maintenance in the production of cellular glutathione (GSH) (Singhal et al., 2011) which can be the reason behind improvement in antioxidant activity in present study.

It could be concluded that, Silymarin can attenuate 3-NPA induced motor deficits and oxidative nitric oxide stress through antioxidative mechanisms. Antioxidant activity evaluated in the present study indicates as well as verify its scavenging free radicals mechanism. Furthermore, favourable enhancement of glutamate transporter and free radical quenching property by silymarin is an important factor observed in the study. More research must be carried out to focus exclusively on potential antioxidative mechanism.

---

Fig. 7. Effect of silymarin on Reduced Glutathione level in 3-NP treated rats. Values are expressed as mean ± S.D. *p < 0.001 as compared to control, *p < 0.05 as compared to 3-NP.

3-NP = 3-Nitropropionic acid, SILY = Silymarin.

Fig. 8. Effect of silymarin on Catalase activity in 3-NP treated rats. Values are expressed as mean ± S.D. *p < 0.001 as compared to control, *p < 0.05 as compared to 3-NP.

3-NP = 3-Nitropropionic acid, SILY = Silymarin.
Fig. 9. Effect of silymarin on superoxide dismutase activity in 3-NP treated rats. Values are expressed as mean ± S.D. a p < 0.001 as compared to control, b p < 0.05 as compared to 3-NP.
3-NP = 3-Nitropropionic acid, Sily = Silymarin.

CRediT authorship contribution statement

Priyanka Chandolia: conducted the experiment, wrote the manuscript. All author read and approve the manuscript and all data were generated in-house and that no paper mill was used. Vikram Rahi: wrote the manuscript. All author read and approve the manuscript and all data were generated in-house and that no paper mill was used. Puneet Kumar: conceived and design of research, wrote the manuscript. All author read and approve the manuscript and all data were generated in-house and that no paper mill was used.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

The data has been shared in manuscript as results

References

AbouZid, S.F., Chen, S.N., Pauli, G.F., 2016. Silymarin content in Silybum marianum populations growing in Egypt. Ind. Crop. Prod. 83, 729–737.
Aswar, U., Chepuruwar, S., Shintre, S., Aswar, M., 2017. Telmisartan attenuates diabetes induced depression in rats. Pharmacol. Rep. 69 (2), 358-364.
Baluchnejadmojarad, T., Roghani, M., Mafakheri, M., 2010. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci. Lett. 480 (3), 206–210.
Bishnoi, M., Chopra, K., Kulkarni, S.K., 2008. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors. Psychopharmacology (Berl) 196 (2), 243–254.
Borah, A., et al., 2013. Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action. CNS Neurosci. Ther. 19 (11), 847–853.
Chandolia Jr., P., 2021. Neuroprotective effect of silymarin against 3-nitropropionic acid-induced Huntington’s like symptoms in rats. Alzheimer’s Dementia 17, e049910.
Coles, C.J., Edmundson, D.E., Singer, T.P., 1979. Inactivation of succinate dehydrogenase by 3-nitropropionate. J. Biol. Chem. 254 (12), 5161–5167.
Datta, S., Jamwal, S., Deshmukh, R., Kumar, P., 2016. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: possible neurotransmitters and neuroinflammation modulation. Eur. J. Pharmacol. 771, 229–235.
Domise, M., Vingteux, V., 2016. AMF in neurodegenerative diseases. In: AMP-Activated Protein Kinase. Springer, pp. 153–177.
Durzen, F., Pinto, M., Sousa, E., 2018. Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals 11 (2), 44.
Ellman, G.L., 1959. Arch.: tissue sulfhydryl groups. Biochem.Biophys Biophys. 82, 70–77.
Evans, S.W., Douglas, I., Rawlins, M.D., Wexler, N.S., Tabrizi, S.J., Smeeth, L., 2013. Prevalence of adult Huntington’s disease in the UK based on diagnoses recorded in general practice records. J. Neurol. Neurosurg. Psychiatry 84 (10), 1156–1160.
Fisher, E.R., Hayden, M.R., 2014. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov. Disord. 29 (3), 105–114.
Garcia, M., Vanhoutte, P., Pages, C., Besson, M.-J., Brouillet, E., Caboche, J., 2002. The C60 fullerene reduces 3-nitropropionic acid-induced striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. J. Neurosci. 22 (6), 2174–2184.
Geggadavalli, G., Robinson, M.B., Trotti, D., Rassen, T., 2001. Regulation of glutamate transporters in health and disease. In: Progress in Brain Research, vol. 132. Elsevier, pp. 267–286.
Gonchar, O.O., et al., 2021. C60 fullerene reduces 3-nitropropionic acid-induced oxidative stress disorders and mitochondrial dysfunction in rats by modulation of p53, bcl-2 and Nrf2 targeted proteins. Int. J. Mol. Sci. 22 (11), 5444.
Gornall, A.G., Bardwill, C.J., David, M.M., 1949. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 177 (2), 751–766.
Green, L.C., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R., 1982. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal. Biochem. 126 (1), 1–138.
Huang, L.S., et al., 2006. 3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J. Biol. Chem. 281 (9), 853–863.
Kim, H.S., et al., 2015. Current status of Huntington’s disease in Korea: a nationwide survey and national registry analysis. J Mov Disord 8 (1), 14.
Kono, Y., 1978. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch. Biochem. Biophys. 186 (1), 189–195.
Krakovskaya, N.A., Bezprozvanny, I.B., 2021. Normalization of calcium balance in striatal neurons in Huntington’s disease: sigma 1 receptor as a potential target for therapy. Biochemistry (Moscow) 86 (4), 471–479.
Kumar, P., Kumar, A., 2009. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog. Neuro Psychopharmacol. Biol. Psychiatr. 33 (1), 100–108.
Kumar, P., Kumar, A., 2009. Protective Role of Sertraline against 3-nitropropionic Acid-Induced Cognitive Dysfunction and Redox Ratio in Striatum , Cortex and hippocampus of Rat Brain, vol. 47, pp. 715–722.
Kumar, P., Kalia, H., Kumar, A., 2010. Huntington’s disease: pathogenesis to animal models. Pharmacol. Rep. 62 (1), 1–14.
Kumar, P., Kalia, H., Kumar, A., 2011. Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington’s-like symptoms: a comparative study. J. Psychopharmacol. 25 (10), 1399–1411. https://doi.org/10.1177/0269881110364269.
Kumar, P., Kalonia, H., Kumar, A., 2012. Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. Eur. J. Pharmacol. 674 (2–3), 265–274.

Kumar, A., Vashist, A., Kumar, P., Kalonia, H., Mishra, J., 2012. Protective Effect of HMG CoA Reductase Inhibitors against Running Wheel Activity Induced Fatigue, Anxiety like Behavior, Oxidative Stress and Mitochondrial Dysfunction in Mice, pp. 1526–1536.

Kumar, A., Vashist, A., Kumar, P., Kalonia, H., Mishra, J., 2012. Protective Effect of HMG CoA Reductase Inhibitors against Running Wheel Activity Induced Fatigue, Anxiety like Behavior, Oxidative Stress and Mitochondrial Dysfunction in Mice, pp. 1526–1536.

Luck, H., 1963. Methods of Enzymatic Analysis, "Enzyme Assays in Vivo. Academic Press, New York, London.

Mady, F.M., Essa, H., El-Ammawi, T., Abdelkader, H., Hussein, A.K., 2016. Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis. Drug Des. Dev. Ther. 10, 1101.

Pogacnik, I., Ota, A., Ulrich, N.P., 2020. An overview of crucial dietary substances and their modes of action for prevention of neurodegenerative diseases. Cells 9 (3), 576.

Rodríguez-Campuzano, A.G., Ortega, A., 2021. Glutamate Transporters: critical components of glutamatergic transmission. Neuropharmacology, 108602.

Singh, S., Jamwal, S., Kumar, P., 2015. Piperine enhances the protective effect of curcumin against 3-NP induced neurotoxicity: possible neurotransmitters modulation mechanism. Neurochem. Res. 40 (8), 1758–1766.

Singhal, N.K., Srivastava, G., Patel, D.K., Jain, S.K., Singh, M.P., 2011. Melatonin or silymarin reduces maneb-and parquat-induced Parkinson's disease phenotype in the mouse. J. Pineal Res. 50 (2), 97–109.

Suganya, S.N., Sumathi, T., 2016. Rutin a dietary flavonoid protects against altered neurobehavioral, membrane bound enzymes and striatal damage induced by 3-nitropropionic acid in male Wistar rats. Int. J. Pharmacognosy Phytochem. Res. 8 (7), 1191–1199.

Túnez, I., Sánchez-López, F., Agüera, E., Fernández-Bolaino, R., Sánchez, F.M., Tanet-Cuevas, I., 2011. Important role of oxidative stress biomarkers in Huntington's disease. J. Med. Chem. 54 (15), 5602–5606.

Valkova, V., Důránová, H., Bíliková, J., Habán, M., 2020. Milk thistle (silybum marianum): a valuable medicinal plant with several therapeutic purposes. J. Microbiol. Biotechnol. Food Sci. 9 (5), 836–843.

Wang, M., et al., 2015a. A new type of liquid silymarin proliposome containing bile salts: its preparation and improved hepatoprotective effects. PLoS One 10 (12), e0143625.

Wang, X.-J., Cao, Q., Zhang, Y., Su, X.-J., 2015b. Activation and regulation of caspase-6 and its role in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 55, 553–572.

Wang, L., et al., 2017. Effect of Praeruptorin C on 3-nitropropionic acid induced Huntington's disease-like symptoms in mice. Biomed. Pharmacother. 86, 81–87.

Wills, E., 1966. Mechanisms of lipid peroxide formation in animal tissues. Biochem. J. 99 (3), 667.

Wiprich, M.T., Zanandrea, R., Attenhofen, S., Bonan, C.D., 2020. Influence of 3-nitropropionic acid on physiological and behavioral responses in zebrafish larvae and adults. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 234, 108772.

Xiang, C., Zhang, S., Dong, X., Ma, S., Cong, S., 2018. Transcriptional dysregulation and post-translational modifications in polyglutamine diseases: from pathogenesis to potential therapeutic strategies. Front. Mol. Neurosci. 11.